ArticleEpilepsy & behavior reports2026
Effect of Fenfluramine on convulsive seizures and rescue medication usage: A case series of adults within the Lennox-Gastaut syndrome spectrum.
Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adults with Developmental and epileptic encephalopathies (DEE) within the Lennox-Gastaut Syndrome (LGS) spectrum suffer disabling convulsive seizures which may remain refractory and are associated with increased risk of hospitalisations and death. Fenfluramine (FFA) was licenced in the UK for seizures associated with LGS in March 2025. Methods: Adjunctive FFA was assessed in a series of 6 adults with a genetic DEE within the LGS spectrum treated for refractory convulsive seizures. The minimum period of observation was 9 months (range 9-32 months). 3 patients commenced FFA pre-licencing on compassionate grounds. 4 patients had a VNS, 5 patients were prescribed concomitant Cannabidiol. Reduction in convulsive seizures and reduction in use of rescue medications/ frequency of hospitalisations was also assessed. Caregiver responses were recorded using the Clinical Global Improvement of Change (CGI-I). Results: At last follow up, all 6 patients remained on FFA. No significant side effects were observed. There was a significant reduction in seizures at last follow up ( Conclusion: Adjunctive FFA was tolerated without significant side effects and associated with a significant reduction in convulsive seizures in this limited cohort. Corresponding reduction in use of rescue medications and hospitalisations has the potential to impact on both patient and caregiver quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.